Eylea vs Xiidra
Side-by-side cost comparison based on Medicare Part D data
Eylea
Aflibercept
Manufactured by Regeneron
Xiidra
Lifitegrast
Manufactured by Novartis
Xiidra costs 70% less per claim than Eylea ($229.00 vs $752.00). A generic version of Xiidra is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Eylea | Xiidra |
|---|---|---|
| Avg Cost Per Claim | $752.00 | $229.00 |
| Total Medicare Spending | $3.7B | $567.0M |
| Total Beneficiaries | 685,000 | 298,000 |
| Total Claims | 4,860,000 | 2,480,000 |
| Annual Cost/Patient | $5,334.00 | $1,903.00 |
| Year-over-Year Change | -8.3% | +4.8% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Regeneron | Novartis |
| Condition | Eye Diseases | Eye Diseases |
| Generic Name | Aflibercept | Lifitegrast |
Eylea vs Xiidra: What the Data Shows
Eylea (Aflibercept) and Xiidra (Lifitegrast) are both used to treat eye diseases. Based on Medicare Part D data, Xiidra costs $229.00 per claim, which is 70% less than Eylea at $752.00 per claim.
Medicare spent $3.7B on Eylea and $567.0M on Xiidra. In terms of patient reach, Eylea serves more beneficiaries (685,000 vs 298,000).
Year-over-year spending changed -8.3% for Eylea and +4.8% for Xiidra.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Xiidra is cheaper at $229.00 per claim, compared to $752.00 for Eylea. That makes Xiidra about 70% less expensive per claim based on Medicare Part D data.
Yes, both Eylea and Xiidra are used to treat eye diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Aflibercept and generic Lifitegrast can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $3.7B on Eylea covering 685,000 beneficiaries, and $567.0M on Xiidra covering 298,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.